Other OTC - Delayed Quote USD

EPIRUS Biopharmaceuticals, Inc. (EPRSQ)

0.0000

(0.00%)

At close: February 6 at 2:34 PM EST

Advanced Chart

Loading Chart for EPRSQ

9/21 12:03 PM

DELL

Previous Close 0.0000
Open 0.0000
Bid 0.1450 x 5000
Ask 0.1600 x 70000
Day's Range 0.0000 - 0.0000
52 Week Range 0.0000 - 0.0001
Volume 1
Avg. Volume 0
Market Cap (intraday) 1,571
Beta (5Y Monthly) -14.94
PE Ratio (TTM) --
EPS (TTM) -0.0100
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.

epirusbiopharma.com